Set For ‘Implosion’ … Biotech

IBB & SPBIO, at The Danger Point®

Each one in their own way, as we’ll see below.

From a Wyckoff standpoint, we’ve identified one of, if not the sector(s) most likely to decline the farthest and fastest in a bear market.

Without question, biotech contains the overriding ‘elephant’ that’s literally affecting everything else on the planet (not advice, not a recommendation).

As stated in the tag-line above, the two indices in question are IBB (large cap) and SPBIO (small cap).

IBB, has Amgen, Gilead and Vertex, as the top three while SPBIO, has more speculative (i.e., losing more money) Beam, Twist and Fate.

Index IBB has $342.8-Bil, combined for the top three while SPBIO has only $6.5-Bil, combined.

So, it makes sense the more speculative ‘cash burning inferno‘ TWST, is in the SPBIO. 🙂

On to the charts

IBB Weekly

IBB has formed a decisive resistance area as shown.

The fourth attempt which pushed above the prior three levels (and retraced), puts IBB, at The Danger Point®

Next up is the SPBIO.

It’s much weaker and thus the focus for any short opportunities (not advice, not a recommendation).

SPBIO ($SPSIBI), Weekly

While IBB, has moved higher, to an up-thrust over the past nine weeks, SPBIO during that time, has languished.

Note: The chart scales are identical. Scrolling up and down, one can visually see the weakness of SPBIO.

SPBIO, also reached all-time highs, six months before IBB.

Getting Closer-In: SPBIO

We’re going to look at the hourly chart.

SPBIO, Hourly

Those who are long-time visitors to this site will instantly recognize the set-up: ‘Spring-to-Up-Thrust

This Friday, tomorrow, is a shortened trading day.

There’s a potential we’ll have a small blip higher into the up-thrust zone.

Conversely, for 3X Leveraged Inverse Fund LABD, the potential is for a temporary move lower.

Leveraged Inverse LABD, Hourly

This is how it looks for LABD.

Note for the inverse fund, the ‘spring’ on SPBIO, becomes the ‘up-thrust’ on LABD.

Positioning

Not advice, not a recommendation

Wednesday’s downside action in LABD, resulted in the LABD-22-10, position being stopped out with an overall gain around 7.12%.

There have already been several disruptions to the company’s trading platform and data line over the past month and we’ve not even got started with market chaos.

Recall that just recently, the Canadian market went off-line for several hours. We should consider these events the ‘norm’, on a go-forward basis.

As a result, a standing order (in the market) is in place to go long LABD (short SPBIO) at the execution price of LABD @ 18.62.

That order may or may not be modified as we go into the open tomorrow morning.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech … Possibly, FATE(AL)

Trend-Lining @ -99%, Annualized

Is biotech about to go ‘flat-line’?

It’s not just biotech.

As The Maverick of Wall St. presents in his latest video, linked herethe entire market is poised for its next leg down.

In that video, estimates for that next leg are anywhere from -30% to -90%.

Fate Therapeutics FATE, Daily

FATE, is one of our ‘three amigos‘ of the sector, SPBIO.

The daily chart shows a confirmed, multi-hit trend line that’s declining at over -99%, annualized

FATE, isn’t the only one in the ‘- 99%’, crowd

TWST, is also trending lower at -99%, and BEAM, is running a close second at -98%, annualized.

Summary

Today, Friday (mid-session), is the last trading day before a holiday weekend.

During such days, we typically have an upward (low volume) bias.

With that, there’s still just a bit more trading room for FATE to contact the right side trendline.

Of course, what happens next will be the important part.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Three Amigos of Biotech

BEAM, TWST & FATE

It looks like having a real (positive) P/E, may be about to be important.

The prior biotech update said that so far, no P/E, negative P/E, and ‘no money down’ was not affecting the sector.

That is, until now.

Well, ok. I made up the ‘no money down’, part. 🙂

That little jest does not take away from the fact, biotech SPBIO, and its top three weightings, BEAM, TWST and FATE, have all reversed, decisively to the downside.

For the week just ended, BEAM is down – 22.86%, TWST down – 19.18%, and FATE down – 14.16%.

Back at the ranch in the IBB index, Moderna (MRNA) is also down – 14.65% for the week.

So, we have confirmation the entire industry is now continuing its downward course.

Contrast the reversal of index SPBIO, at – 7.04%, with S&P (SPY) at – 1.16%, and the market itself is telling us where to go for opportunity (not advice, not a recommendation).

At this point, all three amigos (BEAM, TWST, FATE) are in downward trading channels.

Trading channel for BEAM is the most aggressive. The weekly chart is below.

Beam Therapeutics (BEAM) Weekly

If BEAM maintains its channel for the rest of this year, the chart below shows the target area(s) for price action.

The coming week may let us know if this channel will be confirmed or negated.

Recall, the S&P is topping out and appears to be reversing.

Goldman says the squeeze is over but that ‘downside is limited’.

We’ll see.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279